Close menu




DEFENCE THERAPEUTICS INC

Photo credits: pixabay.com

Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

  • Biotechnology
  • Pharma
  • Investments

According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

Read

Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

  • AI
  • Biotechnology
  • Investments

The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and C3.ai. However, the biotech sector has recently started to climb again. Where are the opportunities for investors?

Read

Commented by Nico Popp on September 13th, 2023 | 08:30 CEST

Biotech: Poison cocktail or miracle cure? Defence Therapeutics, MorphoSys, Pfizer

  • Biotechnology
  • Pharma

Biotech stocks represent both light and dark. At the end of 2020, BioNtech turned the tide of the pandemic with its Comirnaty vaccine. But many shareholders have also had to endure losses. An example of a loss-maker is the share of the SDAX stock MorphoSys. Between 2020 and 2022, the share lost more than 80%. But what were the reasons for the decline? Are there biotech companies that offer better prospects? We shed light on three stocks from the biotech and healthcare sectors.

Read

Commented by Stefan Feulner on September 7th, 2023 | 08:00 CEST

Biotech with tailwind - Newron Pharmaceuticals, Defence Therapeutics, BioNTech

  • Biotechnology
  • Pharma

There is a lot of activity in the biotechnology sector, even though the broadly diversified Nasdaq Biotech Index reflects this with a performance of only 1% since the beginning of the year. In addition to the increasing number of acquisitions by Big Pharma, promising technologies from second-tier companies are performing extremely well. Furthermore, the surging COVID-19 statistics are instilling hope in vaccine producers as they aim to revive their slumping sales.

Read

Commented by Juliane Zielonka on August 24th, 2023 | 07:00 CEST

Defence Therapeutics, Bayer, Palantir - Milestones, Power Shifts and Mishmash

  • Biotechnology
  • Software
  • Technology

The radiopharmaceuticals market is expected to grow to USD 13.818 billion by 2028. In collaboration with Orano Group, Defence Therapeutics has developed innovative radioactive cancer therapies that destroy cancer at the cellular level, thereby increasing efficacy and minimizing side effects. According to Defence Therapeutics CEO Sebastien Plouffe, this partnership will lead to top-tier therapies in a growing market. Meanwhile, heads are rolling at Bayer, as CEO Bill Anderson has big plans and is replacing key positions with promising candidates. Employees of the British NHS have probably spoken a bit too much. The US company Palantir has been awarded five NHS contracts without competitive bidding and is currently the favorite for a multi-million dollar contract in the healthcare sector. Find out what this means for investors here.

Read

Commented by Armin Schulz on August 16th, 2023 | 05:40 CEST

BioNTech, Defence Therapeutics, Bayer - Who will have trend-setting news first?

  • Biotechnology
  • Pharma

Pharmaceutical and biotech stocks are among the most volatile sectors in the financial markets. Single news stories about new developments or product announcements can not only cause short-term price swings but also have long-term implications, increasing both risk and opportunity for investors. If a breakthrough drug is developed, old preparations can become obsolete - this is good for the innovative company but detrimental to established market participants. As an investor, it is advisable to select specific companies and anticipate directional news through some research.

Read

Commented by André Will-Laudien on August 7th, 2023 | 07:55 CEST

Wild times - quarterly figures on the move! Tupperware, Defence Therapeutics, PayPal and Amazon under the magnifying glass!

  • Biotechnology
  • Software
  • Investments

After a pronounced summer rally on the stock markets, there have been individual setbacks in early August. It should come as no surprise that the reaction to quarterly figures can sometimes be more intense. Often, stocks have simply run too far and experienced a healthy consolidation; in the case of Tupperware, the opposite is probably the case. Here, too many speculators have positioned themselves on the short side, and there were hopeful reports. We analyze a few highlights of the last week.

Read

Commented by Stefan Feulner on August 2nd, 2023 | 09:15 CEST

Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi

  • Biotechnology
  • Pharma
  • AI

There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.

Read

Commented by Juliane Zielonka on July 13th, 2023 | 07:40 CEST

Defence Therapeutics, Bayer AG, Rheinmetall: Patents, price jump and billions of euros

  • Biotechnology
  • Pharma
  • armaments

The global biotechnology market is estimated to grow at a CAGR of 12.8% from 2023 to 2030. This has prompted Defence Therapeutics to secure numerous patents for their innovative platform technology ACCUM™. The platform is the linchpin for therapies in the fight against globally prevalent cancers such as lung, breast, and pancreatic cancer. Defence Therapeutics focuses on strengthening the body's immune system to defend against evil invaders. Cancer is also a topic at Bayer AG. The share price jumps as rumors circulate that the Group intends to divest its agricultural division - including Monsanto and the weedkiller suspected of causing cancer. Rheinmetall can report a further plus. Both the German and Dutch armies are ordering airborne vehicles worth billions. Whether these orders are intended solely for Ukraine will become clearer as the latest news unfolds regarding NATO's activities.

Read

Commented by Armin Schulz on July 6th, 2023 | 07:55 CEST

TUI, Defence Therapeutics, Plug Power - Who has the potential for a rally?

  • Biotechnology
  • travel
  • Energy

The search for stocks with the potential for a rally is an exciting and promising task for investors. There are several approaches and strategies to find appropriate stocks. One commonly used approach is fundamental analysis, which examines a company's financial health, business models, growth prospects and other fundamental factors. Solid fundamental analysis can help identify companies with strong potential for future growth. We have chosen three companies with strong upside potential.

Read